Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2022 09:10 ET | Source: Celularity, Inc.

Celularity Presents Preclinical Data on CYNK-101, its Allogeneic Genetically-Modified Natural Killer Cell Therapy Candidate, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting

FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies and...
October 06, 2022 08:00 ET | Source: Celularity, Inc.

Celularity Promotes Two Executives in Executive Leadership Team

FLORHAM PARK, N.J., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placenta-derived allogeneic cell therapies,...
October 03, 2022 08:00 ET | Source: Celularity, Inc.

Celularity Appoints Adrian Kilcoyne, M.D., M.P.H., M.B.A., as Chief Medical Officer

FLORHAM PARK, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies,...
September 27, 2022 08:00 ET | Source: Celularity, Inc.

Celularity to Present at Jefferies Cell and Genetic Medicine Summit

FLORHAM PARK, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies,...
September 26, 2022 08:00 ET | Source: Celularity, Inc.

Celularity Publishes New Data in Frontiers in Immunology Demonstrating Placental-derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-infected Cells In Vitro

FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies,...
September 15, 2022 14:29 ET | Source: Celularity, Inc.

Celularity Enters Into $150 Million Pre-Paid Advance Agreement with Yorkville

FLORHAM PARK, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies,...
September 06, 2022 16:10 ET | Source: Celularity, Inc.

Celularity Announces Participation in Upcoming Investor Conferences

FLORHAM PARK, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies,...
August 09, 2022 16:10 ET | Source: Celularity, Inc.

Celularity Reports Second Quarter 2022 Financial Results and Corporate Update

- Announced first patient treated in Phase 1/2a clinical trial for CYNK-101 in first-line advanced HER2 positive gastric and gastroesophageal junction (G/GEJ) cancers - - Completed a $30 million...
July 27, 2022 08:00 ET | Source: Celularity, Inc.

Celularity Announces Treatment of First Patient in Phase 1/2a Clinical Trial for NK Cell Therapy CYNK-101, in Development for the First-Line Treatment of Advanced HER2 Positive Gastric and Gastroesophageal Junction (G/GEJ) Cancers

CYNK-101 is an investigational genetically modified natural killer (NK) cell therapy designed to synergize with antibody therapeutics for difficult to treat cancers of high unmet medical need U.S....
June 08, 2022 16:10 ET | Source: Celularity, Inc.

Celularity To Be Added To The Russell 3000® Index And The Small-Cap Russell 2000®

FLORHAM PARK, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell...